Healing from within
Conquering lymphatic disorders, restoring the body’s immune system
Latest News
Fibralign Sponsors International Research Seminar
Fibralign hosted the Lymphedema Summit on January 23, 2022, an international research seminar focused on “Advancements in Lymphedema Surgical Treatment.” This special event featured a gathering of the leading surgeons and researchers in this field and took...
Fibralign Selected as a UCSF Rosenman Institute Innovator
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...
UChicago Medicine Enrolling Patients in Lymphbridge™ Clinical Study For Surgical Treatment Of Breast Cancer-Related Lymphedema
NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment April 14, 2021 – The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge™, a randomized clinical study to evaluate a...
About Us
Fibralign is an award-winning, commercial-stage Stanford-spinout that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge Collagen Matrix, which has now been used in over 750 surgeries by leading surgeons in 19 countries for the treatment of secondary lymphedema, a global chronic disease that currently has no cure.
BioBridge® Collagen Matrix
-
- BioBridge is a novel thread-like scaffold that has been shown in preclinical and clinical studies to repair damaged lymphatic tissue.
- FDA 510(k) cleared Class II device* for use in soft tissue repair.
- CE mark approved, Class III device for surgical treatment of lymphedema.
- KFDA approval (South Korea).
- Commercially available now in the US, Europe, South Korea and Middle East.
* BioBridge has not been approved by the FDA for treatment of lymphedema.
Nanoweave® Technology
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.
Grants, Awards, Partners and Collaborators
Fibralign has been recognized for its vision and potential to impact lives globally.
We are supported in our mission by world class partners and collaborators.
